PDF(Pubmed)
Abstract：
UNASSIGNED: Hypothalamic obesity represents a clinical condition within the broader spectrum of obesity that frequently eludes detection and appropriate diagnosis. This subset of obesity is characterized by a dearth of established predictive markers and a paucity of standardized therapeutic protocols. The advent and rising prominence of glucagon-like peptide-1 (GLP-1) receptor agonists in the obesity treatment landscape present novel therapeutic avenues for hypothalamic obesity management. Nonetheless, critical inquiries persist concerning the efficacy of GLP-1 receptor (GLP-1R) agonists in this context, particularly regarding their central mechanisms of action and specific impact on hypothalamic obesity.
UNASSIGNED: In this narrative review, we concentrate on analyzing research papers that delineate the detection and function of GLP-1 receptors across various hypothalamic and cerebral regions. Additionally, we examine clinical research papers and reports detailing the application of GLP-1 receptor agonists in treating hypothalamic obesity. Furthermore, we include a concise presentation of a clinical case from our unit for contextual understanding.
UNASSIGNED: Currently, the clinical evidence supporting the efficacy of GLP-1 receptor agonists in hypothalamic obesity, as well as the diverse characteristics of this obesity subtype, remains insufficient. Preliminary data suggest that GLP-1R agonists might offer an effective treatment option, albeit with variable outcomes, particularly in younger patient cohorts. From a mechanistic perspective, the presence of GLP-1 receptors in various hypothalamic and broader brain regions potentially underpins the efficacy of GLP-1R agonists, even in instances of hypothalamic damage. Nevertheless, additional research is imperative to establish the functional relevance of these receptors in said brain regions.
UNASSIGNED: GLP-1R agonists represent a potential therapeutic option for patients with hypothalamic obesity. However, further clinical and basic/translational research is essential to validate the efficacy of these drugs across different presentations of hypothalamic obesity and to understand the functionality of GLP-1R in the diverse brain regions where they are expressed.
UNASSIGNED: In this narrative review, we concentrate on analyzing research papers that delineate the detection and function of GLP-1 receptors across various hypothalamic and cerebral regions. Additionally, we examine clinical research papers and reports detailing the application of GLP-1 receptor agonists in treating hypothalamic obesity. Furthermore, we include a concise presentation of a clinical case from our unit for contextual understanding.
UNASSIGNED: Currently, the clinical evidence supporting the efficacy of GLP-1 receptor agonists in hypothalamic obesity, as well as the diverse characteristics of this obesity subtype, remains insufficient. Preliminary data suggest that GLP-1R agonists might offer an effective treatment option, albeit with variable outcomes, particularly in younger patient cohorts. From a mechanistic perspective, the presence of GLP-1 receptors in various hypothalamic and broader brain regions potentially underpins the efficacy of GLP-1R agonists, even in instances of hypothalamic damage. Nevertheless, additional research is imperative to establish the functional relevance of these receptors in said brain regions.
UNASSIGNED: GLP-1R agonists represent a potential therapeutic option for patients with hypothalamic obesity. However, further clinical and basic/translational research is essential to validate the efficacy of these drugs across different presentations of hypothalamic obesity and to understand the functionality of GLP-1R in the diverse brain regions where they are expressed.
摘要：
■下丘脑肥胖代表肥胖的更广泛范围内的临床状况,其经常逃避检测和适当的诊断。肥胖的这一子集的特征在于缺乏已建立的预测性标志物和缺乏标准化的治疗方案。胰高血糖素样肽-1（GLP-1）受体激动剂在肥胖治疗领域的出现和日益突出，为下丘脑肥胖管理提供了新的治疗途径。尽管如此，在这种情况下，关于GLP-1受体（GLP-1R）激动剂的有效性的关键询问仍然存在，特别是关于它们的主要作用机制和对下丘脑肥胖的具体影响。
■在这篇叙述性评论中，我们专注于分析描述GLP-1受体在不同下丘脑和大脑区域的检测和功能的研究论文.此外,我们审查了详细介绍GLP-1受体激动剂在治疗下丘脑肥胖中应用的临床研究论文和报告.此外，我们包括来自我们单位的临床病例的简要介绍，以进行上下文理解。
■目前，支持GLP-1受体激动剂在下丘脑肥胖中疗效的临床证据，以及这种肥胖亚型的不同特征，仍然不够。初步数据表明，GLP-1R激动剂可能提供有效的治疗选择，尽管结果可变，特别是在年轻的患者队列中。从机械的角度来看，GLP-1受体在各种下丘脑和更广泛的大脑区域的存在可能支持GLP-1R激动剂的功效，即使在下丘脑损伤的情况下。然而，进一步的研究是必要的，以确定这些受体在所述脑区的功能相关性。
■GLP-1R激动剂代表了下丘脑肥胖患者的潜在治疗选择。然而,进一步的临床和基础/转化研究对于验证这些药物在下丘脑肥胖的不同表现中的疗效以及了解GLP-1R在其表达的不同脑区的功能至关重要.
■在这篇叙述性评论中，我们专注于分析描述GLP-1受体在不同下丘脑和大脑区域的检测和功能的研究论文.此外,我们审查了详细介绍GLP-1受体激动剂在治疗下丘脑肥胖中应用的临床研究论文和报告.此外，我们包括来自我们单位的临床病例的简要介绍，以进行上下文理解。
■目前，支持GLP-1受体激动剂在下丘脑肥胖中疗效的临床证据，以及这种肥胖亚型的不同特征，仍然不够。初步数据表明，GLP-1R激动剂可能提供有效的治疗选择，尽管结果可变，特别是在年轻的患者队列中。从机械的角度来看，GLP-1受体在各种下丘脑和更广泛的大脑区域的存在可能支持GLP-1R激动剂的功效，即使在下丘脑损伤的情况下。然而，进一步的研究是必要的，以确定这些受体在所述脑区的功能相关性。
■GLP-1R激动剂代表了下丘脑肥胖患者的潜在治疗选择。然而,进一步的临床和基础/转化研究对于验证这些药物在下丘脑肥胖的不同表现中的疗效以及了解GLP-1R在其表达的不同脑区的功能至关重要.
